Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses.

Toussaint PJ, Perlbarg V, Bellec P, Desarnaud S, Lacomblez L, Doyon J, Habert MO, Benali H; Benali, for the Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Nov 1;63(2):936-46. doi: 10.1016/j.neuroimage.2012.03.091. Epub 2012 Apr 10.

PMID:
22510256
2.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.

3.

Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study.

Takahashi R, Ishii K, Senda M, Ito K, Ishii K, Kato T, Makishi Y, Nishio T, Ikari Y, Iwatsubo T; Japanese Alzheimer’s Disease Neuroimaging Initiative.

Ann Nucl Med. 2013 Jun;27(5):452-9. doi: 10.1007/s12149-013-0704-x. Epub 2013 Mar 13.

PMID:
23483370
4.

The Alzheimer's disease-related glucose metabolic brain pattern.

Teune LK, Strijkert F, Renken RJ, Izaks GJ, de Vries JJ, Segbers M, Roerdink JB, Dierckx RA, Leenders KL.

Curr Alzheimer Res. 2014;11(8):725-32.

PMID:
25212911
5.

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Li Y, Rinne JO, Mosconi L, Pirraglia E, Rusinek H, DeSanti S, Kemppainen N, Någren K, Kim BC, Tsui W, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2169-81. doi: 10.1007/s00259-008-0833-y. Epub 2008 Jun 20.

6.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175
7.

Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.

Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A.

J Nucl Med. 2016 Feb;57(2):204-7. doi: 10.2967/jnumed.115.163717. Epub 2015 Nov 19.

8.

(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J.

Cochrane Database Syst Rev. 2014 Jul 23;(7):CD010386. doi: 10.1002/14651858.CD010386.pub2. Review.

PMID:
25052054
9.

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.

Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative.

Radiology. 2013 Feb;266(2):583-91. doi: 10.1148/radiol.12120010. Epub 2012 Dec 11.

10.

Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.

Tosun D, Schuff N, Jagust W, Weiner MW; Alzheimer''s Disease Neuroimaging Initiative.

Neurodegener Dis. 2016;16(1-2):87-94. doi: 10.1159/000439257. Epub 2015 Nov 12.

PMID:
26560336
11.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
12.

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A.

J Nucl Med. 2005 Oct;46(10):1625-32.

13.

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A.

Curr Alzheimer Res. 2010 Feb;7(1):56-66.

PMID:
20205671
14.

Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.

Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K.

J Alzheimers Dis. 2011;25(4):695-706. doi: 10.3233/JAD-2011-100996.

PMID:
21498904
15.

[Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].

Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla J, Portilla-Quattrociocchi H, Medina-Quiroz P, Ortega F, Rodríguez E, Mateo I, Vázquez-Higuera JL, de Arcocha M, Carril JM.

Rev Esp Med Nucl. 2011 Sep-Oct;30(5):301-6. doi: 10.1016/j.remn.2011.03.010. Epub 2011 Jun 2. Spanish.

16.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.

PMID:
20385246
17.

Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.

Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Brewer JB, Hoh CK, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

Radiology. 2010 Sep;256(3):932-42. doi: 10.1148/radiol.10091402.

18.

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ.

J Nucl Med. 2008 Mar;49(3):390-8. doi: 10.2967/jnumed.107.045385. Epub 2008 Feb 20.

19.

18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis.

Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC.

J Cereb Blood Flow Metab. 2006 Sep;26(9):1213-21. Epub 2006 Mar 8.

PMID:
16525414
20.

18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.

Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC.

Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006. Epub 2014 Mar 11.

Supplemental Content

Support Center